Home > Healthcare > Biotechnology > Biotechnology R&D > Biopharmaceutical Fermentation Systems Market

Biopharmaceutical Fermentation Systems Market Trends

  • Report ID: GMI9589
  • Published Date: May 2024
  • Report Format: PDF

Biopharmaceutical Fermentation Systems Market Trends

  • Manufacturers are significantly investing in the development of advanced monitoring and control systems for biopharmaceutical fermentation. These systems incorporate real-time analytics, sensors, and automation technologies to facilitate accurate monitoring of critical process parameters, prompt identification of deviations, and the implementation of adaptive control strategies aimed at enhancing bioprocess efficiency and product quality.
  • The adoption of single-use biopharmaceutical fermentation systems is increasing, due to its benefit over traditional reusable counterparts. For example, companies in biopharmaceuticals can streamline production processes by employing pre-sterilized components such as single-use bioreactors from manufacturers like Sartorius Stedim Biotech and Thermo Fisher Scientific Inc. These single use pre-sterilized components eliminate the need for time-consuming cleaning and sterilization between batches, reducing downtime and operational costs while ensuring product quality and safety.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The biopharmaceutical fermentation systems market size was valued at USD 11.5 billion in 2023 and is anticipated to grow at 6% CAGR from 2024 – 2032, owing to growing demand for biopharmaceuticals and hefty investments for developing new biopharmaceuticals.

The upstream products segment in the market held 62.2% share in 2023, driven by the increasing investments in biopharmaceutical research for the development of new and advanced therapies.

North America biopharmaceutical fermentation systems market accounted for 41.4% share in 2023 and is predicted to reach USD 7.7 billion by 2032, attributed to the presence of large number of biopharmaceutical companies offering advanced treatment options.

Agilent Technologies, Becton, Dickinson and Company, Bioengineering AG, Cellexus Limited, Danaher Corporation, Eppendorf AG, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc., Getinge Group, Lonza Group AG, Merck KGaA, Nova Biomedicals, Sartorius Stedim Biotech, Thermo Fisher Scientific Inc., and ZETA

Biopharmaceutical Fermentation Systems Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 15
  • Tables & Figures: 214
  • Countries covered: 22
  • Pages: 123
 Download Free Sample